Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

Cited by (285)

Items 101–200 of 285

1. Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium
   Philip T. Sager, Jonathan H. Seltzer, J. Rick Turner, Jeffrey L. Anderson, William Robert Hiatt, Peter Russell Kowey, Judith J. Prochaska, Norman Stockbridge, William B. White · 2015 · American Heart Journal
2. The Effects of Nutritional Deficiencies, Smoking, and Systemic Disease on Orthopaedic Outcomes
   Byron F. Stephens, G. Andrew Murphy, William M. Mihalko · 2013 · Journal of Bone and Joint Surgery
3. Tratamiento del Tabaquismo
   Sergio Bello · 2011 · Revista chilena de cardiología
4. Cardiovascular effects of pharmacologic therapies for smoking cessation
   Diana M Sobieraj, William B. White, William L. Baker · 2012 · Journal of the American Society of Hypertension
5. Temas de actualidad en cardiología: riesgo vascular y rehabilitación cardiaca
   Enrique Galve, Almudena Castro, Alberto Cordero, Regina Dalmau, Lorenzo Fácila, Aránzazu García-Romero, Pilar Mazón, Marcelo Sanmartı́n, Angeles Alonso Garcia · 2012 · Revista Española de Cardiología
6. Update in Cardiology: Vascular Risk and Cardiac Rehabilitation
   Enrique Galve, Eduardo Alegría, Alberto Cordero, Lorenzo Fácila, Jaime Fernández de Bobadilla, Carla Lluís-Ganella, Pilar Mazón, Carmen de Pablo Zarzosa, José Ramón González‐Juanatey · 2014 · Revista Española de Cardiología (English Edition)
7. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease
   Daniel Kotz, Wolfgang Viechtbauer, Colin R Simpson, Onno C. P. van Schayck, Robert West, Aziz Sheikh · 2017 · Thorax
8. Varenicline and cardiovascular adverse events: a perspective review
   Yohalakshmi Chelladurai, Sonal Singh · 2014 · Therapeutic Advances in Drug Safety
9. Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable
   Gilles Montalescot, Grupo de Trabajo de la Sociedad Europea de Cardiología sobre diagnóstico y tratamiento de la cardiopatía isquémica estable, Udo P Sechtem, Stephan Achenbach, Felicita Andreotti, Chris Arden, Andrzej Budaj, Raffaele Bugiardini, Filippo Crea, Thomas Cuisset et al. · 2014 · Revista Española de Cardiología
10. Bupropion for Smoking Cessation in Patients Hospitalized With Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Sonia Marzia Grandi, Avi Shimony, Mark Jeffrey Eisenberg · 2013 · Canadian Journal of Cardiology
11. Combined nicotine patch with gum versus nicotine patch alone in smoking cessation in Hong Kong primary care clinics: a randomised controlled trial
    Maria Kwan Wa Leung, Dan Bai, Benjamin Hon Kei Yip, M. Y. Fong, Petty M. H. Lai, Phoebe Lai, Irene S. Y. Lai, Zoe H. W. Lam, Andrew T. F. Leung, Dorothy K Y To et al. · 2019 · BMC Public Health
12. Smoking cessation decreases arterial blood pressure in hypertensive smokers: A subgroup analysis of the randomized controlled trial GENTSMOKING
    Patrícia Viviane Gaya, Guilherme Wesley Peixoto da Fonseca, Lucas Tsuyoshi Tanji, Tânia Ogawa Abe, Maria Janieire de Nazaré Nunes Alves, Paulo Caleb Júnior Lima Santos, Fernanda Marciano Consolim‐Colombo, Jaqueline Schölz Issa · 2024 · Tobacco Induced Diseases
13. Hesperidin blocks varenicline-aggravated atherosclerotic plaque formation in apolipoprotein E knockout mice by downregulating net uptake of oxidized low-density lipoprotein in macrophages
    Mitsuhisa Koga, Yuki Kanaoka, Koshun Inada, Sai Omine, Yasufumi Kataoka, Atsushi Yamauchi · 2020 · Journal of Pharmacological Sciences
14. Identification and in vitro pharmacological characterization of a novel and selective α7 nicotinic acetylcholine receptor agonist, Br-IQ17B
    Jingshu Tang, Bingxue Xie, Xiling Bian, Yu Xue, Ningning Wei, Jingheng Zhou, Yuchen Hao, Gang Li, Liangren Zhang, Ke-wei Wang · 2015 · Acta Pharmacologica Sinica
15. Design, Synthesis and Discovery of Picomolar Selective α4β2 Nicotinic Acetylcholine Receptor Ligands
    Venkata Mahidhar Yenugonda, Yingxian Xiao, Edward D. Levin, Amir H. Rezvani, Thao Phuong Tran, Nour Al‐Muhtasib, Niaz Sahibzada, Teresa Xie, Corinne Wells, Susan K. Slade et al. · 2013 · Journal of Medicinal Chemistry
16. Internet Versus In-Person Counseling for Patients Taking Varenicline for Smoking Cessation
    Kent J. DeZee, Jennifer S. Wink, Christopher M. Cowan · 2013 · Military Medicine
17. Does smoking cessation with varenicline worsen vascular endothelial function?
    Akira Umeda, Toru Kato, Tateki Yamane, Heiichi Yano, Tamio Ieiri, Kazuya Miyagawa, Hiroshi Takeda, Yasumasa Okada · 2013 · BMJ Open
18. Therapeutic concentrations of varenicline in the presence of nicotine increase action potential firing in human adrenal chromaffin cells
    Arik J. Hone, J. Michael McIntosh, Lola Rueda‐Ruzafa, J. Passas, Cristina De Castro Guerín, Jesús Blázquez, Carmen González Enguita, Almudena Albillos · 2016 · Journal of Neurochemistry
19. Current and Emerging Pharmacotherapeutic Options for Smoking Cessation
    Kristin Carson‐Chahhoud, Malcolm P Brinn, Thomas A. Robertson, Rachada To-A-Nan, Adrian Esterman, Matthew J. Peters, Brian J. Smith · 2013 · Substance Abuse Research and Treatment
20. Varenicline aggravates plaque formation through α7 nicotinic acetylcholine receptors in ApoE KO mice.
    M. Koga, Yuki Kanaoka, Yuma Ohkido, Naoka Kubo, Kaoru Ohishi, Keita Sugiyama, A. Yamauchi, Y. Kataoka · 2014 · Biochemical and Biophysical Research Communications - BBRC
21. Human nicotinic receptors in chromaffin cells: characterization and pharmacology
    Almudena Albillos, J. Michael McIntosh · 2017 · Pflügers Archiv - European Journal of Physiology
22. Expression of α3β2β4 nicotinic acetylcholine receptors by rat adrenal chromaffin cells determined using novel conopeptide antagonists
    Arik J. Hone, Lola Rueda‐Ruzafa, Thomas J. Gordon, Joanna Gajewiak, Sean B. Christensen, Tino Dyhring, Almudena Albillos, J. Michael McIntosh · 2020 · Journal of Neurochemistry
23. The Relationship between Smoking and Depression Post-Acute Coronary Syndrome
    Andrew M. Busch, Belinda Borrelli, Adam Matthew Leventhal · 2011 · Current Cardiovascular Risk Reports
24. Safety of Varenicline Tartrate and Counseling Versus Counseling Alone for Smoking Cessation: A Randomized Controlled Trial for Inpatients (STOP Study)
    Kristin Carson‐Chahhoud, B. J. Smith, Malcolm P Brinn, Matthew J. Peters, Robert Fitridge, Simon Andrea Koblar, Jim Jannes, Kuljit Singh, Antony Veale, Sharon J. Goldsworthy et al. · 2014 · Nicotine & Tobacco Research
25. Smoking Hazards and Cessation
    Neal L. Benowitz, Paul G. Brunetta · 2015 · Elsevier eBooks
26. Functional Interactions of Varenicline and Nicotine With nAChR Subtypes Implicated in Cardiovascular Control
    Hans Rollema, Cristina Russ, Theodore C. Lee, Raymond S Hurst, Daniel Bertrand · 2014 · Nicotine & Tobacco Research
27. Les outils du sevrage tabagique en 2018
    J. Abdul-Kader, Guillaume Airagnes, Samuel d’Almeida, Frédéric Limosin, Anne-Laurence Le Faou · 2018 · Revue de Pneumologie Clinique
28. Adverse drug reactions
    Arden R. Barry, Sheri L. Koshman, Glen J. Pearson · 2014 · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
29. Improvement in skin color achieved by smoking cessation
    Toshiji Ishiwata, Kuniaki Seyama, Tetsuji Hirao, Kazunori Shimada, Yoshiteru Morio, K. Miura, A. Kume, Haruhi Takagi, Ken Takahashi · 2012 · International Journal of Cosmetic Science
30. Varenicline aggravates atherosclerotic plaque formation in nicotine-pretreated ApoE knockout mice due to enhanced oxLDL uptake by macrophages through downregulation of ABCA1 and ABCG1 expression
    Mitsuhisa Koga, Yuki Kanaoka, Mana Okamoto, Yuki Nakao, Koshun Inada, Saki Takayama, Yasufumi Kataoka, Atsushi Yamauchi · 2019 · Journal of Pharmacological Sciences
31. A randomized controlled trial of the efficacy and safety of varenicline for smoking cessation after acute coronary syndrome: Design and methods of the Evaluation of Varenicline in Smoking Cessation for Patients Post-Acute Coronary Syndrome trial
    Sarah B. Windle, Iqbal R. Bata, Mina Madan, Beth L. Abramson, Mark Jeffrey Eisenberg · 2015 · American Heart Journal
32. Preventive aspects in peripheral artery disease
    Saurabh Aggarwal, Rohit Seth Loomba, Rohit Romesh Arora · 2012 · Therapeutic Advances in Cardiovascular Disease
33. Pharmacologic Agents for Tobacco Dependence Treatment: 2011 Update
    James Taylor Hays, David D. McFadden, Jon O. Ebbert · 2011 · Current Atherosclerosis Reports
34. Varenicline for smoking cessation: Is it a heartbreaker?
    James Taylor Hays · 2011 · Canadian Medical Association Journal
35. Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting
    André Pacheco Silva, Jaqueline Schölz Issa, Tânia Ogawa Abe, Gabriela Gouveia Pinheiro, Patrícia Viviane Gaya, Alexandre C. Pereira, Paulo Caleb Júnior Lima Santos · 2016 · BMC Cardiovascular Disorders
36. Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study
    David J. Graham, Kunthel By, Stephen J. McKean, Andrew D. Mosholder, Cynthia J. Kornegay, Judith A. Racoosin, Jessica C. Young, Mark S Levenson, Thomas E. MaCurdy, Chris M. Worrall et al. · 2014 · Pharmacoepidemiology and Drug Safety
37. Varenicline enhances oxidized LDL uptake by increasing expression of LOX-1 and CD36 scavenger receptors through α7 nAChR in macrophages.
    Yuki Kanaoka, M. Koga, Keita Sugiyama, Kaoru Ohishi, Y. Kataoka, A. Yamauchi · 2017 · Toxicology
38. Blood pressure, Fluid Retention and the Cardiovascular Risk of Drugs
    Robert P. Blankfield · 2012 · Future Cardiology
39. “Tobacco dependence treatment makes no sense because”…: Rebuttal of commonly-heard arguments against providing tobacco dependence treatment in the hospital setting
    James Balmford, Jens A. Leifert, Andreas Jaehne · 2014 · BMC Public Health
40. Risk of neuropsychiatric and cardiovascular adverse events following treatment with varenicline and nicotine replacement therapy in the UK Clinical Practice Research Datalink: a case–cross‐over study
    Kyla H Thomas, Neil M Davies, Amy E. Taylor, Gemma M. J. Taylor, David Gunnell, Richard Michael Martin, Ian Douglas · 2020 · Addiction
41. What are the effects of varenicline compared with nicotine replacement therapy on long-term smoking cessation and clinically important outcomes? Protocol for a prospective cohort study
    Neil M Davies, Gemma M. J. Taylor, Amy E. Taylor, Kyla H Thomas, Frank Windmeijer, Richard Michael Martin, Marcus Robert Munafo · 2015 · BMJ Open
42. Varenicline: quantifying the risk
    H. Takagi, T. Umemoto · 2011 · Canadian Medical Association Journal
43. Fatality following a suicidal overdose with varenicline
    Christophe Pol Stove, Els A. De Letter, Michel H A Piette, Willy E. Lambert · 2012 · International Journal of Legal Medicine
44. Smoking Cessation Interventions for Lung Cancer Patients
    Kristin Carson‐Chahhoud, Zafar Ahmad Usmani, Thomas A. Robertson, Satya Mysore, Malcolm P Brinn · 2013 · Lung Cancer Management
45. The Prevalence of and Factors Associated with the Use of Smoking Cessation Medication in Korea: Trend between 2005–2011
    Dong Wook Shin, Beomseok Suh, Sohyun Chun, Juhee Cho, Sang-Ho Yoo, Seok Joong Kim, Bumjo Oh, Belong Cho · 2013 · PLoS ONE
46. Treatment With Bupropion and Varenicline for Smoking Cessation and the Risk of Acute Cardiovascular Events and Injuries: a Swedish Case-Crossover Study
    Joel Monárrez‐Espino, Maria Rosaria Galanti, Jenny Hansson, Imre Janszky, Karin C Söderberg, Jette Möller · 2017 · Nicotine & Tobacco Research
47. Varenicline: cardiovascular safety
    L. Samuels · 2011 · Canadian Medical Association Journal
48. Smoking Cessation Strategies After Acute Coronary Syndrome
    Anum Nazir, Smrthi Shetty Ujjar, M. Seddiki, Mala Jheinga, Lampson M. Fan · 2025 · Journal of Clinical Medicine
49. Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement therapy for smoking cessation: study protocol of a retrospective cohort study using the QResearch general practice database
    Daniel Kotz, Colin R Simpson, Wolfgang Viechtbauer, Onno C. P. van Schayck, Robert West, Aziz Sheikh · 2014 · BMJ Open
50. A TEN YEAR OVERVIEW OF SURGICAL AND INTERVENTIONAL ARRHYTHMOLOGY IN RUSSIA. SERVICE PECULIAR FEATURES IN THE FAR EAST
    С А Богачевская, Богачевский Александр Николаевич · 2017 · Social Aspects of Population Health
51. Varenicline: quantifying the risk
    David John Woods, M. D. Caswell · 2011 · Canadian Medical Association Journal
52. Nephrotoxic effects of varenicline as the most effective drug used for smoking cessation: a preliminary experimental study
    Akif Koç, Haydar Ali Erken, Fatma Emel Koçak, Arzu Yay, Aydın Güçlü, Erhan Sarı, Hasan Şimşek, Gözde Özge Önder, Osman Genç · 2015 · International Urology and Nephrology
53. Varenicline promotes endothelial cell migration by lowering vascular endothelial-cadherin levels via the activated α7 nicotinic acetylcholine receptor–mitogen activated protein kinase axis
    Mitsuhisa Koga, Yuki Kanaoka, Keita Sugiyama, Kaoru Ohishi, Yuka Ejima, Mami Hisanaga, Yasufumi Kataoka, Atsushi Yamauchi · 2017 · Toxicology
54. Interventions for smoking cessation in patients admitted with Acute Coronary Syndrome: a review
    Omar Chehab, Habib Abbas Dakik · 2017 · Postgraduate Medical Journal
55. Transient ischemic attack: Part II. Risk factor modification and treatment.
    B. Brent Simmons, Annette B. Gadegbeku, Barbara Cirignano · 2012 · PubMed
56. An Update About Tobacco and Cancer: What Clinicians Should Know
    Steven A. Schroeder · 2012 · Journal of Cancer Education
57. Evaluation of varenicline usage on ventricular repolarization after smoking cessation
    Duygu İlke Yıldırım, Mert İlker Hayıroğlu, Neriman Ünal, Mehmet Ali Eryılmaz · 2018 · Annals of Noninvasive Electrocardiology
58. Recent Updates of Pharmacotherapy for Smoking Cessation
    Ju Sam Hwang, Cheol Min Lee · 2021 · Korean Journal of Family Practice
59. Recomendaciones para la cesación de la adicción al tabaco en Colombia: guía de práctica clínica basada en la evidencia
    Luz Helena Alba, Raúl Murillo, Nelci Becerra, Nelson Páez, Alejandra Cañas, Catalina Mosquera, Juan Sebastián Castillo, Natalia Castellanos Camacho, Javier Gómez, Plutarco García-Herreros et al. · 2012 · Biomédica
60. Role of nicotine receptor partial agonists in tobacco cessation
    Pratima Murthy, Nivedita Maity, Prabhat Chand · 2014 · Indian Journal of Psychiatry
61. Smoking cessation: strategies and effects in primary and secondary cardiovascular prevention
    Stefan Cristian Stanel, Pilar Rivera‐Ortega · 2021 · Panminerva Medica
62. Comparison of Cardiovascular Safety for Smoking Cessation Pharmacotherapies in a Population-Based Cohort in Australia
    Alys Havard, Stephanie K. Y. Choi, Sallie‐Anne Pearson, Clara Kayei Chow, Duong Thuy Tran, Kristian B. Filion · 2021 · JAMA Network Open
63. Smoking cessation in Asians: focus on varenicline
    Dan Xiao, Shuilian Chu, Chen Wang · 2015 · Patient Preference and Adherence
64. Varenicline: quantifying the risk
    Robert P. Blankfield · 2011 · Canadian Medical Association Journal
65. Reducing the Cardiovascular Disease Burden
    Behnood Bikdeli, José Augusto Barreto‐Filho · 2012 · Circulation Cardiovascular Quality and Outcomes
66. Safety and Effectiveness of Varenicline in Korean Smokers: A Nationwide Post-Marketing Surveillance Study
    Minsu Ock, Ji Soo Shin, Seung Won Ra · 2022 · Patient Preference and Adherence
67. 3D-QSAR and 3D-QSSR models of negative allosteric modulators facilitate the design of a novel selective antagonist of human α4β2 neuronal nicotinic acetylcholine receptors
    Brandon J. Henderson, Crina M. Orac, Iwona Maciągiewicz, Stephen C. Bergmeier, Dennis B. McKay · 2011 · Bioorganic & Medicinal Chemistry Letters
68. Comparative Safety of Smoking Cessation Pharmacotherapies During a Government-Sponsored Reimbursement Program
    Greg Carney, Malcolm Maclure, Suzanne C. Malfair Taylor, Ken L. Bassett, James M Wright, Colin R. Dormuth · 2020 · Nicotine & Tobacco Research
69. Varenicline: quantifying the risk
    Brian S. Alper · 2011 · Canadian Medical Association Journal
70. Evidence of the effectiveness and safety of first-line smoking cessation pharmacotherapy
    Evangelia Liakoni, Neal L. Benowitz · 2021 · European Respiratory Society eBooks
71. Prediction of Adverse Cardiovascular Events of Noncardiovascular Drugs through Drug‐Target Interaction Networks
    Francisco J Azuaje, Yvan Devaux, Daniel R. Wagner · 2012 · Clinical and Translational Science
72. Can it be Ethical to Apply Limited Resources in Low-income Countries to Ineffective, Low-reach Smoking Cessation Strategies? A Reply to Bitton and Eyal
    Simon F Chapman, Ross MacKenzie · 2012 · Public Health Ethics
73. Status of Evidence-based Medicine Education in Undergraduate Pharmacy Curricula
    Junichi Sasaki, Kyoko Kitazawa, Takeo Nakayama · 2018 · YAKUGAKU ZASSHI
74. Top 20 research studies of 2011 for primary care physicians.
    Mark H. Ebell, Roland M Grad · 2012 · PubMed
75. Effects of varenicline on sympatho-vagal balance and cue reactivity during smoking withdrawal: a randomised placebo-controlled trial
    Helge Haarmann, Alexandra Gossler, Peter Herrmann, Slavtcho Bonev, Xuan Phuc Nguyen, Gerd P Hasenfuss, Stefan Andreas, Tobias Raupach · 2016 · Tobacco Induced Diseases
76. Síndrome coronario agudo: una complicación grave e infrecuente en la deshabituación tabáquica con vareniclina
    Carmen Laura Sanz Sanz, E. Meyer García-Sípido, Monica Fuentes Pônte, F. del Nogal Sáez · 2013 · Medicina Clínica
77. Varenicline: quantifying the risk
    Edward N. Squire · 2011 · Canadian Medical Association Journal
78. Tobacco Smoking Is a Medical Problem. We Ought to Treat It Like One
    Ravi Kalhan, John T. Wilkins, Brian L. Hitsman · 2017 · American Journal of Respiratory and Critical Care Medicine
79. Safety of Varenicline in Patients With Cardiovascular Disease
    Stacy L. Haber, Virginia Boomershine, Erin C. Raney · 2013 · Journal of Pharmacy Practice
80. Evidence Behind FDA Alerts for Drugs with Adverse Cardiovascular Effects: Implications for Clinical Practice
    Daniel M. Rackham, M. Herink, Ian G. Stevens, Natalie M. Cardoza, Harleen Singh · 2014 · Pharmacotherapy
81. Varenicline-Induced Coronary Thrombosis
    Arzu Kalaycı, Ayşegül Eren, Gönenç Kocabay, Can Yücel Karabay, Çetin Geçmen, Cevat Kırma · 2013 · Annals of Pharmacotherapy
82. The Pharmacogenetics of Nicotine Dependence and Smoking Cessation Therapies
    Patti W. Adams · 2014 · Journal of Pharmacogenomics & Pharmacoproteomics
83. Methods of smoking cessation
    ApexaB Patel, Adit Patel, BaldevV Patel · 2016 · The journal of National Accreditation Board for Hospitals and Healthcare Providers
84. Smoking Cessation Guidelines in the Primary Care Setting
    Hye‐Mi Noh, Yu‐Jin Paek, Cheol Min Lee · 2013 · Korean Journal of Family Practice
85. Cytisine increased smoking cessation in adults
    Daniella A. Zipkin · 2012 · Annals of Internal Medicine
86. Cardiovascular Adverse Events Associated with Smoking-Cessation Pharmacotherapies
    Abhishek Sharma, Saurabh Thakar, Carl J. Lavie, Jalaj Garg, Parasuram Melarcode Krishnamoorthy, Ondřej Sochor, Armin Arbab‐Zadeh, Edgar Lichstein · 2014 · Current Cardiology Reports
87. Flaws in Current Clinical Trial Design: Need for Intermediate Markers
    Joseph Yeboah · 2011 · Journal of Postgenomics Drug & Biomarker Development
88. Risikofaktor „Rauchen“
    Joachim Weil, Jan Stritzke, Heribert Schunkert · 2011 · Der Internist
89. Advancing Drug-Drug Interaction Prediction using Multi-Modal Feature Integration with Graph Neural Networks
    Ernest Chinonso Chianumba, Hao Liu, Aparna S. Varde, Yan Zhuang · 2025 · IEEE International Conference on Bioinformatics and Biomedicine (BIBM)
90. Parkinsonism Related to Varenicline in a Patient During Smoking Cessation
    Ali Ulvi Uca, Hasan Hüseyin Kozak, Faruk Uğuz, Haluk Gümüş · 2015 · Journal of Clinical Psychopharmacology
91. Treatment of tobacco addiction and the cardiovascular specialist
    Tobias Raupach, Jamie Brown · 2012 · Current Opinion in Cardiology
92. Varenicline induced acute interstitial nephritis in the setting of idiopathic membranous glomerulonephritis
    W. Kwong, Christine A. White · 2013 · BMC Nephrology
93. Rehabilitation (EACPR) Developed with the special contribution of the European Association for Cardiovascular Prevention & Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) : The Fifth
    Christiaan J. Vrints, David Wood, José Luis Zamorano, Faiez M. Zannad, Şehnaz Karadeniz, Alessandro Mezzani, Eva Prescott, Shah B J Ebrahim, Giuseppe Germanò, Richard F. Hobbs et al. · 2013
94. A Narrative Review of Smoking Cessation Practices in Jordan
    Sami Saqf el Hait · 2017 · Journal of pharmacology & clinical research
95. Comparison of Cardiovascular Risks following Smoking Cessation Treatments Using Varenicline vs. NRT among Schizophrenic Smokers
    I-Hsuan Wu, Hua Chen, Patrick Bordnick, Ekere James Essien, Michael Johnson, Ronald J Peters, Susan Abughosh · 2017 · Archives of Psychiatry and Mental Health
96. Update in Cardiology: Vascular Risk and Cardiac Rehabilitation
    Enrique Galve, Almudena Castro, Alberto Cordero, Regina Dalmau, Lorenzo Fácila, Aránzazu García-Romero, Pilar Mazón, Marcelo Sanmartı́n, Angeles Alonso Garcia · 2012 · Revista Española de Cardiología (English Edition)
97. In smokers with COPD, neither varenicline nor bupropion was linked to increased CV or neuropsychiatric risk vs NRT
    Catherine Kress, Ngozi U. Obi, Allan V. Prochazka · 2017 · Annals of Internal Medicine
98. PRESCRIPTION FOR CONFLICT: WHY THE ALLIANCE BETWEEN THE PHARMACEUTICAL INDUSTRY AND THE ANTI‐TOBACCO MOVEMENT IS NOT IN THE BEST INTERESTS OF SMOKERS
    Patrick Basham, John C. Luik · 2012 · Economic Affairs
99. Eficacia y seguridad del uso de medicamentos para la cesación de la adicción al tabaco: revisión de guías de práctica clínica
    Alejandra Cañas, Luz Helena Alba, Nelci Becerra, Raúl Murillo, Nelson Páez, Catalina Mosquera, Plutarco Garcia-Herreros, Juan Sebastian Castillo · 2015 · Revista de Salud Pública
100. Clinical Psychopharmacology Update: Additional Safety Concerns for Using Varenicline (Chantix) for Smoking Cessation Treatment
     Thomas J. Tobin, Mary L. Tobin · 2015 · Issues in Mental Health Nursing